Bristol-Myers Squibb

BMY · NYSE

$61.68+$2.85 (+4.84%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $58.83

Latest news

Press releaseOct 19, 6:59 AM ETBusiness Wire
Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026
NewsOct 13, 1:35 PM ET
10 Health Care Stocks With Whale Alerts In Today’s Session
NewsOct 12, 12:59 PM ETVandana Singh
Why Is Contineum Therapeutics Stock Falling Monday?
NewsOct 12, 8:02 AM ETVandana Singh
Why Is Bristol Myers Squibb Stock Gaining Monday?
NewsOct 12, 7:03 AM ET
Bristol Myers Squibb Announces Topline Results From Unit RayzeBio's Planned Interim Analysis Of ACTION-1 Trial; RYZ101 Study Met Primary Endpoint With Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival By Blinded Independent Central Review, And Safety Results Consistent With Known Safety Profile
Press releaseOct 12, 6:55 AM ETBusiness Wire
Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs
NewsOct 12, 6:51 AM ET
Bristol Myers Squibb's Admilparant Meets Phase 3 Primary Endpoint in Idiopathic Pulmonary Fibrosis Trial
Press releaseOct 12, 6:50 AM ETBusiness Wire
Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint
NewsOct 8, 12:27 PM ETVandana Singh
Bristol Myers Squibb’s Zenbexus Delivers Major Blood Cancer Win, Cuts Progression Risk 51%
Press releaseOct 8, 6:59 AM ETBusiness Wire
Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...
NewsOct 7, 1:44 PM ETVandana Singh
Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure
Press releaseOct 1, 6:59 AM ETBusiness Wire
Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement
Press releaseSep 30, 5:32 PM ETBusiness Wire
U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*
NewsSep 30, 2:48 PM ET
FDA Approves Bristol Myers Squibb's Camzyos As First Treatment For Children With Obstructive Hypertrophic Cardiomyopathy Weighing At Least 30 kg
NewsSep 30, 1:35 PM ET
10 Health Care Stocks With Whale Alerts In Today’s Session
NewsSep 30, 10:29 AM ETVandana Singh
Tirzepatide or Semaglutide? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli Lilly's Tirzepatide (CORRECTED)
Press releaseSep 25, 10:00 AM ETBusiness Wire
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
NewsSep 18, 1:52 PM ETVandana Singh
This $3 Biotech Could Be Worth $11.45, Analyst Says
Press releaseSep 18, 6:59 AM ETBusiness Wire
Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026
NewsSep 17, 11:45 AM ETVandana Singh
Bristol Myers Squibb’s Psoriatic Arthritis Pill Shows Durable Efficacy After Two Years
Press releaseSep 17, 6:59 AM ETBusiness Wire
Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
Press releaseSep 16, 6:59 AM ETBusiness Wire
Bristol Myers Squibb Announces Dividend
Press releaseSep 10, 8:30 AM ETGlobe Newswire
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
NewsSep 8, 11:13 AM ETVandana Singh
Bristol Myers Says Cell Therapy Shows Promise For Heavily Pretreated Blood Cancer Patients
Press releaseSep 8, 6:59 AM ETBusiness Wire
Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...
NewsSep 4, 11:33 AM ETVandana Singh
A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths
Press releaseAug 29, 11:00 AM ETBusiness Wire
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
Press releaseAug 26, 9:20 AM ETGlobe Newswire
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
NewsAug 25, 7:39 AM ETAvi Kapoor
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
NewsAug 14, 12:07 PM ETVandana Singh
Bristol Myers Squibb Gets FDA Nod For Novel Multiple Myeloma Treatment
Press releaseAug 13, 5:12 PM ETBusiness Wire
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
Press releaseAug 13, 8:00 AM ETPRNewswire
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
Press releaseAug 10, 9:01 AM ETBusiness Wire
Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas
NewsAug 3, 1:13 PM ETVandana Singh
AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus
NewsAug 3, 1:05 PM ETPiero Cingari
Oil Sinks 6%, Nasdaq 100 Rallies On Iran Talks: Stock Market Today
NewsAug 3, 12:45 PM ETThe Arora Report
Yen Intervention And Falling Oil Help Stocks, But Selling In Korea Throws A Monkey Wrench
NewsAug 3, 8:42 AM ETKaustubh Bagalkote
Why Is Bristol-Myers Squibb Stock Surging Monday?
NewsAug 3, 8:27 AM ETRishabh Mishra
Jim Cramer Senses a 'Fake Out' in Rumored AstraZeneca, Bristol Myers Squibb $400 Billion Mega-Merger
NewsAug 3, 8:01 AM ETAvi Kapoor
AstraZeneca, GameStop, Snap And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
NewsAug 3, 4:33 AM ETAvi Kapoor
Why Atkore Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket
NewsAug 2, 4:12 PM ET
AstraZeneca, Bristol Myers Squibb Reportedly in Talks for $400 Billion Merger
NewsJul 29, 8:23 AM ETAvi Kapoor
How To Earn $500 A Month From Bristol-Myers Squibb Stock Ahead Of Q2 Earnings
NewsFeb 5, 12:23 PM ETAvi Kapoor
Dow Tumbles Over 400 Points; Bristol Myers Reports Strong Q4 Results
NewsJan 28, 3:00 PM ET
P/E Ratio Insights for Bristol-Myers Squibb
NewsDec 31, 7:20 AM ETAvi Kapoor
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
NewsDec 1, 8:30 AM ETAvi Kapoor
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
NewsNov 3, 8:12 AM ETAvi Kapoor
Cleveland-Cliffs, Meta And Rocket On CNBC's 'Final Trades'
NewsAug 22, 7:41 AM ETAvi Kapoor
ServiceNow, Live Nation Entertainment And A Health Care Stock: CNBC's 'Final Trades'
NewsJul 31, 3:03 AM ETAvi Kapoor
Dow Falls Over 150 Points After Powell's Comments On Rate Cuts: Investor Sentiment Declines, But Fear Index Remains In 'Greed' Zone
NewsJul 31, 2:09 AM ETAvi Kapoor
Microsoft, Apple And 3 Stocks To Watch Heading Into Thursday
NewsJul 9, 4:53 AM ETRishabh Mishra
Warren Buffett's Quiet Dividend Play: 9 High-Yield Stocks Held By A Berkshire Subsidiary

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026

10 Health Care Stocks With Whale Alerts In Today’s Session

Why Is Contineum Therapeutics Stock Falling Monday?

Why Is Bristol Myers Squibb Stock Gaining Monday?

Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs

Bristol Myers Squibb's Admilparant Meets Phase 3 Primary Endpoint in Idiopathic Pulmonary Fibrosis Trial

Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint

Bristol Myers Squibb’s Zenbexus Delivers Major Blood Cancer Win, Cuts Progression Risk 51%

Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...

Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure

Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement

U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*

FDA Approves Bristol Myers Squibb's Camzyos As First Treatment For Children With Obstructive Hypertrophic Cardiomyopathy Weighing At Least 30 kg

10 Health Care Stocks With Whale Alerts In Today’s Session

Tirzepatide or Semaglutide? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli Lilly's Tirzepatide (CORRECTED)

Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma

This $3 Biotech Could Be Worth $11.45, Analyst Says

Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026

Bristol Myers Squibb’s Psoriatic Arthritis Pill Shows Durable Efficacy After Two Years

Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years

Bristol Myers Squibb Announces Dividend

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

Bristol Myers Says Cell Therapy Shows Promise For Heavily Pretreated Blood Cancer Patients

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...

A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Bristol Myers Squibb Gets FDA Nod For Novel Multiple Myeloma Treatment

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

Oil Sinks 6%, Nasdaq 100 Rallies On Iran Talks: Stock Market Today

Yen Intervention And Falling Oil Help Stocks, But Selling In Korea Throws A Monkey Wrench

Why Is Bristol-Myers Squibb Stock Surging Monday?

Jim Cramer Senses a 'Fake Out' in Rumored AstraZeneca, Bristol Myers Squibb $400 Billion Mega-Merger

AstraZeneca, GameStop, Snap And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

Why Atkore Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket

AstraZeneca, Bristol Myers Squibb Reportedly in Talks for $400 Billion Merger

How To Earn $500 A Month From Bristol-Myers Squibb Stock Ahead Of Q2 Earnings

Dow Tumbles Over 400 Points; Bristol Myers Reports Strong Q4 Results

P/E Ratio Insights for Bristol-Myers Squibb

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

Cleveland-Cliffs, Meta And Rocket On CNBC's 'Final Trades'

ServiceNow, Live Nation Entertainment And A Health Care Stock: CNBC's 'Final Trades'

Dow Falls Over 150 Points After Powell's Comments On Rate Cuts: Investor Sentiment Declines, But Fear Index Remains In 'Greed' Zone

Microsoft, Apple And 3 Stocks To Watch Heading Into Thursday

Warren Buffett's Quiet Dividend Play: 9 High-Yield Stocks Held By A Berkshire Subsidiary